ClinicalTrials.gg
RecruitingNCT07460947ONE-D BPDUpdated Aug 5, 2026

A Pilot Trial of One-Day Accelerated TMS and D-cycloserine in Suicidal Patients With Borderline Personality Disorder

A Phase 1/2 interventional study of TMS and D-Cycloserine (DCS) in Borderline Personality Disorder (BPD), sponsored by Mclean Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Mclean Hospital · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Borderline Personality Disorder with a site in United States — 15 open to participants now, 17 under way, none of them phase 3. Borderline Personality Disorder · United States.

Planned enrollment
53rd of 71
20 · median 56
Started
2026
with 2 others
Phase 1/2
2 of 81
1 open now
Primary completion
2027-06
later than 8 of 16 live
Registered
79th of 81
by date
Lead sponsor
4 of 81
Mclean Hospital

Among the 81 studies in Borderline Personality Disorder with a site in United States, this one is the 53rd largest by planned enrollment of the 71 interventional ones that give a count, is one of 3 that started in 2026, is one of 2 in phase 1/2, reaches primary completion later than 8 of the 16 other live ones, and was the 79th registered.

Borderline Personality Disorder

279 studies on the registry are indexed under Borderline Personality Disorder; 70 are open to participants now.

Browse Borderline Personality Disorder studies →

Open to participants now

15 of the 81 studies in Borderline Personality Disorder with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Borderline Personality Disorder studies recruiting now, 18 (37%) set no upper age limit and 30 (61%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Borderline Personality Disorder with a site in United States, or all of them as a file.
02

Study summary

This study tests a new treatment for people with borderline personality disorder (BPD). The treatment combines a medication called D-cycloserine with one day of transcranial magnetic stimulation (TMS).

The main questions it aims to answer are:

  • How many participants complete the treatment?
  • How do participants feel about the treatment?
  • Does the treatment have neurophysiological changes on participants?
  • Does the treatment improve BPD symptoms?
  • Do the benefits last over time?

Participants will be asked to:

  • Come to the clinic for interviews and testing
  • Complete weekly questionnaires for 4 weeks before the treatment day
  • Take D-cycloserine the night before treatment
  • Attend one treatment day at the clinic. On that day, they may receive up to 20 short TMS sessions (each lasting 3 minutes and separated by 30 minutes). This visit may last up to 12 hours.
  • Complete weekly questionnaires for 6 weeks after the treatment day.
03

Conditions studied

  • Borderline Personality Disorder (BPD)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (18+) of any gender
  • Meets criteria for BPD, per assessment with the Structured Clinic Interview for DSM-5 Personality Disorders (SCID-5-PD), BPD Module
  • Moderate to severe SI during the two weeks prior to screening, as indexed by a score of 9 or higher on the Modified Scale for Suicide Ideation - Self Report (Clum \& Yang, 1995)

Exclusion criteria

Exclusion Criteria:

  • Current manic or hypomanic symptoms, as assessed by the Diagnostic Assessment Research Tool (DART) screener and diagnostic modules, where relevant.
  • Current psychotic symptoms not better accounted for by BPD, as assessed by the DART psychotic symptoms screener.
  • Current alcohol or substance use disorder, that in the opinion of a study PIs, is of sufficient severity to impede engagement in treatment or is associated with significant risk of medical withdrawal, as assessed by the DART.
  • Medical documentation or self-report of current anorexia nervosa, bulimia nervosa, or eating disorder not otherwise specified - atypical anorexia nervosa or atypical bulimia nervosa, that is in the opinion of a study PIs is of sufficient severity to be associated with significant medical risks
  • Acute suicide risk, sufficient to require immediate hospitalization;
  • history of traumatic brain injury (TBI) or concussion involving loss of consciousness or amnesia for ≥24 hours;
  • any significant neurological disorder likely to be associated with increased intracranial pressure or cognitive impairment (e.g., epilepsy; Parkinson's disease);
  • diagnosed neurodevelopmental disorder (e.g., autism, downs syndrome; Ehlers-Danlos Syndrome) other than attention-deficit hyperactivity disorder (ADHD) or dyslexia
  • current diagnosis of delirium or dementia;
  • cognitive disorder secondary to a general medical condition
  • Pregnant and breastfeeding people are excluded in line with the studies our protocol is based upon using DCS and aTMS. Assessment of pregnancy will be completed during the 1-week prior to the administration of DCS (i.e., taken the night before TMS treatment), where relevant and according to MGB IRB policy.
  • Participants with to TMS (e.g., metal in head or neck area), or at increased risk for adverse events (e.g., seizure history or markedly heightened risk factors for seizures, serious medical problems, implanted devices) will be excluded.
  • Participants with a known allergy to DCS will be excluded from the study.
  • No patients with involuntary hospitalization status will be recruited for the study.
  • No individuals who are not proficient in English will be recruited for the study
  • Subject does not have a PCP
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    TMS + D-cycloserine

    Open-label combination of TMS and D-cycloserine

    Device: TMS · Drug: D-Cycloserine (DCS)

Interventions

  • DeviceTMS

    TMS will consist of 600 pulses of intermittent theta burst stimulation (iTBS), with 3-minute treatment sessions delivered up to 20 times every 30 minutes for a 12-hour protocol.

    Also known as: iTBS

  • DrugCycloserineStudies of CycloserineCycloserine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will be asked to take a single dose (250mg) of D-cycloserine the night before the treatment day.

06

What researchers measure

Primary outcomes

  1. Acceptability of Intervention Measure (AIM)

    Feasibility of the one-day TMS treatment will be indexed by favorable ratings on the Acceptability of Intervention Measure (AIM). The AIM is a four-item measure that assesses participants' approval of an intervention. Each item is rated on a 5-point scale (completely disagree - completely agree), and total scores indicate greater acceptance of an intervention.

    Time frame: Week 5

  2. Motor-evoked potentials (MEPs)

    MEPS will be recorded before and after treatment sessions 1, 2, 10, and the final session. Specifically, MEPS will be collected within 10 minutes before treatment session onset and within 5 minutes after treatment session completion. An increase in motor-evoked potentials (MEPs) over the TMS treatment course indicates increased plasticity.

    Time frame: Within 10 minutes pre- and 5 minutes post- treatment sessions 1,2,10,and final session

Secondary outcomes

  1. Modified Scale for Suicide Ideation - Self Report (MSSI-SR)

    Suicidal ideation will be assessed using the MSSI-SR. The MSSI-SR is an 18-item self-report measure that assesses the frequency, intensity, and nature of suicidal ideation, plans, and intent across the past week. Responses range from 0 (e.g., does not experience thoughts of suicide) to 3 (e.g., experiences thoughts of suicide many times each day). Total score ranges from 0 to 54, with higher scores indicating greater suicide risk factors and more severe suicidal ideation.

    Time frame: From baseline through to week 11. Taken at week 1, week 3, week 6, week 8, week 10, and week 11, an average of once every two weeks

  2. Distress Tolerance Scale (DTS)

    The DTS is a 15-item self-report questionnaire assessing participant's beliefs about distressing or upsetting feelings on average. Responses range from 1 (strongly agree) to 5 (strongly disagree), and higher average total scores indicate greater distress tolerance.

    Time frame: From baseline through to week 11. Taken at week 1, week 2, week 4, week 7, week 9, and week 11, an average of once every two weeks

  3. Rejection Sensitivity Questionnaire (RSQ)

    The RSQ is an 18-item self-report measure that assesses the level of rejection concern and rejection expectancy an individual has in nine common hypothetical situations. Rejection concern scores range from 1 (very unconcerned) to 6 (very concerned), and rejection expectancy scores range from 1 (very unlikely) to 6 (very likely). Sensitivity scores (between 1 and 36) are produced for each situation by multiplying the two scores. The total score (between 1 and 36) represents the average of rejection sensitivity scores across the situations, with higher scores indicating greater rejection sensitivity.

    Time frame: From baseline through to week 11. Taken at week 1, week 7, and week 11

  4. The Brief Version of the Mentalization Scale (MentS-12)

    The MentS-12 is a 12-item self-report measure that assesses an individual's mentalization capacity across self-related mentalization, other-related mentalization, and motivation to mentalize. Responses range from 1 (completely incorrect) to 5 (completely correct), and total higher summed score indicates greater mentalizing capacity.

    Time frame: From baseline through to week 11. Taken at week 1, week 7, and week 11

  5. Social Safeness and Pleasure Scale (SSPS)

    The SPSS is an 11-item self-report measure that assesses the extent to which participants experience their social worlds as safe, warm, and soothing. Responses range from 1 (almost never) to 5 (almost all the time), and total scores range from 11 to 55, with higher scores indicating greater positive feelings in social relationships.

    Time frame: From baseline through to week 11. Taken at week 1, week 7, and week 11

  6. Borderline Symptom List 23 (BSL-23)

    The BSL-23 is a self-report measure that Assesses how much participants suffered from experiences related to BPD. Responses range from 0 (not at all) to 4 (very strong). The total score (0-4) is the average of the 23 items, with higher scores indicating greater BPD symptom severity.

    Time frame: From baseline through to week 11. Taken at week 1, week 7, and week 11

  7. Patient Health Questionnaire 9 (PHQ-9)

    The PHQ-9 is a 9-item self-report measure that assesses depression severity over the past 2 weeks (or otherwise specified). Responses range from 0 (not at all) to 3 (nearly every day), along with a final question about how difficult the endorsed problems made it difficult to do work, take care of things at home, or get along with others (ranging from not difficult at all - extremely difficult). Total summed score indicates depression severity, with higher scores suggesting greater depression severity

    Time frame: From baseline through to week 11. Taken at week 1, week 7, and week 11

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — This is an internal, Phase I study and there are no current plans to share IPD with personnel outside of Mass General Brigham (MGB). In the event that a decision is made in the future to share data from this research study with collaborators outside of MGB, data will be de-identified prior to sharing and will comply with all relevant MGB data sharing policies. The possibility that data may be shared with outside collaborators will be clearly outlined in the informed consent form.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2026
First posted
Mar 10, 2026
StartActual
Jun 10, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2027
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07460947
Lead sponsor
Mclean Hospital
Responsible party
Jenna M. Traynor (Prinicipal Investigator, Mclean Hospital) — Principal investigator
First posted
Mar 10, 2026
Start date
Jun 10, 2026
Primary completion
Jun 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 5, 2026

Study contacts

Alexandra Velev, BA
Contact
avelev@mclean.harvard.edu
617-855-3430
Molly Coyle, BS
Contact
mcoyle3@mgb.org
617-855-2153
Jenna M Traynor, PhD
principal investigator · Mclean Hospital
Joshua Brown, MD, PhD
principal investigator · Mclean Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cycloserine

Start the discussion